Therefore, pro-inflammatory cytokines that interfere with eNOS mRNA levels may reduce eNOS activity and impair vasorelaxation in dyslipidemia (Yoshizumi et al., 1993). The gene discussed is NOS3; the disease is metabolic syndrome.